Haemonetics Co. (NYSE:HAE) Shares Sold by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can trimmed its position in Haemonetics Co. (NYSE:HAE) by 0.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,712 shares of the medical instruments supplier’s stock after selling 188 shares during the period. Great West Life Assurance Co. Can owned approximately 0.06% of Haemonetics worth $2,773,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Financial Gravity Companies Inc. purchased a new position in Haemonetics in the fourth quarter valued at $41,000. Quadrant Capital Group LLC increased its stake in shares of Haemonetics by 708.8% during the first quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 567 shares in the last quarter. Ffcm LLC increased its stake in shares of Haemonetics by 134.4% during the fourth quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock worth $174,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. increased its stake in shares of Haemonetics by 614.5% during the fourth quarter. Advisor Group Inc. now owns 2,022 shares of the medical instruments supplier’s stock worth $203,000 after purchasing an additional 1,739 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Haemonetics during the fourth quarter worth about $203,000. Institutional investors and hedge funds own 98.74% of the company’s stock.

In other news, SVP Jacqueline Scanlan sold 3,646 shares of the firm’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $112.49, for a total value of $410,138.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Simon sold 1,248 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $109.37, for a total transaction of $136,493.76. The disclosure for this sale can be found here. Insiders sold a total of 103,952 shares of company stock worth $10,130,798 over the last ninety days. Insiders own 1.32% of the company’s stock.

Several analysts recently issued reports on HAE shares. Barrington Research reaffirmed an “outperform” rating and set a $116.00 price objective (up previously from $112.00) on shares of Haemonetics in a research note on Wednesday, May 8th. Zacks Investment Research lowered shares of Haemonetics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. Raymond James upgraded shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 target price on the stock in a report on Tuesday, May 14th. Finally, TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $118.60.

HAE traded up $1.04 during trading hours on Friday, hitting $120.34. 723,000 shares of the company’s stock were exchanged, compared to its average volume of 496,003. Haemonetics Co. has a 12-month low of $80.24 and a 12-month high of $120.93. The stock’s 50 day moving average price is $105.44. The stock has a market cap of $5.98 billion, a price-to-earnings ratio of 50.35, a P/E/G ratio of 2.95 and a beta of 0.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.62 and a current ratio of 2.44.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.06. The company had revenue of $249.30 million for the quarter, compared to the consensus estimate of $250.62 million. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 EPS. Analysts predict that Haemonetics Co. will post 2.93 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: What defines an oversold asset?

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.